Today is World Cancer Day, and this year’s theme, #UnitedByUnique, celebrates every individual journey and the power of people-centered care.
At PICI, we’re working toward one goal: turning all cancers into curable diseases. Together, we can create a future without cancer.
#WorldCancerDay #PICI
In the final PICI #BreastCancerAwarenessMonth Research Spotlight, learn about impactful breast cancer research at @UCSF to advance #immunotherapies for patients with breast cancer.
Thanks for following along this month as we shared breast cancer research updates from across the PICI network. Stay tuned for more as PICI’s members and collaborators strive to turn all cancers into curable diseases.
CAR-T therapies have been transformational in blood cancer treatment, but they struggle to have impact in solid tumors like triple-negative breast cancer. In this PICI #BreastCancerAwarenessMonth Research Spotlight, discover research from @WeillCornell to bring the power of CAR-T to breast cancer.
In this PICI #BreastCancerAwarenessMonth Research Spotlight, learn about research from the PICI Center at @mdandersoncancercenter , where Dr. Kenneth Hu is exploring how to overcome barriers to #immunotherapy effectiveness in breast cancer and beyond.
In today’s #BreastCancerAwarenessMonth research spotlight, PICI shares research from the PICI Center at @Stanford.Med , where Dr. Chris McGinnis is investigating how immune pathways influence breast cancer metastasis.
This #BreastCancerAwarenessMonth, PICI is reflecting on the scientific advances across the PICI Network that help accelerate #immunotherapy treatments and cures for people with breast cancer. Today, we spotlight research from the PICI Center at @PennMedicine , on cancer vaccines and next-gen immunotherapies that could shape the future of breast cancer care.
October is #BreastCancerAwarenessMonth, and PICI is highlighting scientific advances in cancer #immunotherapy across the PICI Network. Today’s spotlight is on the PICI Center at @DanaFarber , home to impactful projects that could shape the future of breast cancer care.
PICI is proud to announce Dispatch Bio — a PICI-founded company taking on one of the most persistent challenges in oncology: treating solid tumors, which account for approximately 90% of all cancer diagnoses and represent the most difficult to treat cancers.
Dispatch Bio exemplifies the PICI model: advancing breakthrough science from bench to bedside to marketplace through collaborative innovation.
Read the full press release to learn more: /news/dispatch-bio-launches-to-deliver-universal-treatment-for-solid-tumors-with-novel-immunotherapy-approach/
120+ experts. 3 days. 1 mission. At the 2025 PICI Spring Scientific Retreat, we aligned on what's next in cancer immunotherapy — and how to deliver it faster. From AI to predictive biomarkers and smarter cell therapies, we're moving breakthroughs from bench to bedside with urgency and purpose.
"Why stop now, when we haven't yet realized immunotherapy's full potential?"
In a new @nature_the_journal interview, Ira Mellman, PhD, President of Research at PICI, shares what's next in #CancerImmunotherapy — from curative cell therapies to smarter T cells.
Read more: /articles/d41573-025-00107-w
AI is reshaping cancer care—but only if it delivers for patients.
At #STATBreakthroughWest, PICI CEO @karenknudsenphd joined @ascocancer , @massgeneralbrigham and @statnews to discuss how AI must move from hype to impact. From RADIOHEAD to Xaira Therapeutics, the PICI Network is using AI and biology to speed trials and move bold science toward cures.
When the hardest cancers go unsolved, Anusha Kalbasi, MD, of @stanford.med , gets to work. The PICI Investigator is a recipient of the 2025 CRI Lloyd J. Old STAR Award from @cancerresearchinstitute —recognizing investigators who take on cancer's toughest questions.
Dr. Kalbasi's lab is reshaping cell therapy by engineering T cells with synthetic cytokine receptors, delivering powerful, targeted signals without toxic conditioning chemo.
Now leading a pan-California IL-13Ra2 CAR-T trial for melanoma and rare solid tumors, Dr. Kalbasi is translating science into new hope for patients who need it most.
